124.55 9% 104.83 8% Investment in associated company 397.46 28% 483.96 36% Property, plant and equipment 644.04 46% 558.59 42% Biological assets – dairy cow 45.60 3% 44.28 3% Others 61.05 5% 61.09 4% Total

. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public

/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

from change in fair value of biological assets 9.70 Million Baht. The main cause is the value of economic trees that was recorded in the consolidated financial statements as at 31 December 2016

improvement. Other Transaction In Year 2018, the company recorded Baht 34.0 million from gain on changes in fair value less costs to sell biological asset, gain on sales deposits from land Baht 22.2 million and

cost to sale of biological assets. Financial Cost Financial cost in Quarter 2/2019 was Baht 8.5 Million decreased by Baht 1.3 Million or 13.1% from Q2/2018 mainly from bank loan repayment in 2018. Net

Transaction In Quarter 2/2018, the company recorded Baht 22.2 million from gain on sales of deposits for land, Baht 3.9 million from gain on changes in fair value less costs to sell biological asset and Baht

and internal control of subsidiaries improvement. Other Transaction In Quarter 3/2018, the company recorded Baht 4.0 million from gain on changes in fair value less costs to sell biological asset and

essential for economic development and sustainability. Applying science to Thailand?s resource abundance and biological diversity will bring about better quality of life and economic sustainable development

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public